Innovaderm will be at the EADV Congress in Amsterdam!
2024-08-22
Innovaderm is excited to be attending the EADV congress once again, in Amsterdam this year, from September 25th—28th 2024!
Both our European and North American teams will be waiting for you at booth #B12 to showcase dermatology excellence. Book a meeting with our experts fast!
Innovaderm's full involvement at EADV
Innovaderm participated to various presentations at the congress:
- September 26th, 5:15PM CEST - New Topical and Systemic Treatments - Atopic Dermatitis
- September 27th, 8:45AM CEST - Treatment response of delgocitinib cream according to Chronic Hand Eczema (CHE) subtypes in adults with moderate to severe CHE: results from the Phase 3 DELTA 1, DELTA 2, and DELTA 3 trials
- September 28th, 2:15PM CEST - Investigational Treatments we May Soon be Able to Add to our Armamentarium - Internation Eczema Council
Innovaderm also participated to the following e-Posters:
- Deucravacitinib efficacy in special areas of scalp, fingernails, and palms/soles in plaque psoriasis: results from a phase 3 trial
- Study design of phase 3 trials evaluating rocatinlimab efficacy and safety in moderate-to-severe atopic dermatitis: the ROCKET program
- Efficacy and safety of delgocitinib cream in adults with moderate to severe CHE: pooled results of the Phase 3 DELTA-1 and -2 trials
- Systemic exposure and safety profile of delgocitinib cream in adults with moderate to severe CHE in the Phase 3 DELTA-2 trial
- Long-term safety and efficacy of delgocitinib cream for up to 36 weeks in adults with CHE: results of the Phase 3 open-label extension DELTA-3 trial
- Clinical trial exit interviews in patients with moderate to severe CHE: perspectives on disease burden and its impact on quality of life from participants in the phase 3 DELTA 1 trial
Book some time with our dermatology experts!
Newsletter
Join our science community with Press Forward, our quarterly newsletter. Get the latest in dermatology clinical research. Subscribe now!
Newsletter subscription resources
